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Purpose. CTLA4Ig, a fusion protein of CTLA-4 and Fc of immuno-
globulin (Ig) heavy chain, inhibits the essential costimulatory signal
for full T cell activation via blocking the interaction between CD28
and B7 molecules and renders T cell nonresponsiveness. CTLA4Ig
has been used to control deleterious T cell activation in many experi-
mental systems. We hypothesized that by conjugating CTLA4Ig to
liposomes the efficacy of CTLA4Ig could be enhanced through mul-
tivalent ligand effect, superior targetability, and modification of the
fate of ligated costimulatory molecules.
Methods and Results. Consistent with this hypothesis, liposome-
conjugated CTLA4Ig bound to B7 and blocked their binding sites
more efficiently than free CTLA4Ig, lowering the half maximal dose
for B7 blocking by an order of the magnitude. These results were
similar both in B7-1 expressing p815 cells and in activated macro-
phages. Moreover, CTLA4Ig-liposomes underwent rapid internaliza-
tion upon cell surface binding through B7 molecules. In allogenic
mixed lymphocyte reaction assays, the CTLA4Ig-liposomes were
tested to show effective inhibition of T cell proliferation. In vivo,
however, when CTLA4Ig-liposomes were injected into mice, a sig-
nificant fraction was localized to the reticuloendothelial system
(RES), presumably because of its binding to Fc receptors expressed
on tissue macrophages. The Fc receptor-mediated uptake could be
alleviated by coinjection of anti-FcR monoclonal antibody. In the
mouse engrafted with pancreatic islets of Langerhans underneath the
capsule of one kidney, despite the increased localization in RES,
enhanced accumulation of CTLA4Ig-conjugated liposome was ob-
served in the engrafted kidney compared to the contralateral kidney.
Conclusion. We show that the conjugation of CTLA4Ig to liposome
could increase the efficiency of the targeting by increasing the binding
avidity at cellular level and by increasing the concentration at the
target site in in vivo system. The biodistribution and circulation time
data suggested that the CTLA4Ig-liposomes could be improved upon
minimizing the FcR-mediated uptake by Fc receptor-bearing cells.
Thus, the strategy of conjugating CTLA4Ig to liposomes could be
exploited for immune intervention in transplantation and autoim-
mune diseases for the efficient blocking of costimulation.
KEY WORDS: B7 costimulatory molecules; targeting; CTLA4Ig;
liposomes; islet transplantation.
INTRODUCTION
Two distinct signals are essential for full activation of T
cells: 1) the antigen-specific signal that is generated upon the
engagement of T cell receptor (TCR) by the peptide bound to
the major histocompatibility complex (MHC) on antigen-
presenting cells (APCs); and 2) the costimulatory signal
through the ligation of costimulatory receptors by their li-
gands expressed on APCs (1).
One of the most potent costimulatory signals known to
date is generated through CD28, a molecule expressed con-
stitutively on the surface of T cells. CD28 interacts with two
ligands, B7-1 (CD80) and B7-2 (CD86), both of which are
expressed on the surface of APCs (1). CD28 and CTLA-4 are
two T cell surface receptors for B7-1 and B7-2. Upon binding
to its ligand, CD28 provides an essential costimulatory signal
required for full activation of T cells (1). However, CTLA-4,
a structural homologue of CD28 expressed on T cells, binds to
the same B7 ligands but inhibits T cell activation. This sug-
gests that CTLA-4 regulates T cell activation through a dis-
tinct pathway. The affinity of CTLA-4 for B7 molecules is
20-fold higher than that of CD28 for B7 (2,3). Using these
characteristics, the B7-binding region in the extracellular do-
main of CTLA-4 was fused to the Fc portion of IgG to gen-
erate a soluble protein CTLA4Ig as an agent to inhibit CD28/
B7-mediated costimulation; although the CTLA-4 ectodo-
main can bind monovalently and block B7 molecules, fusion
to the Fc portion of IgG generates a bivalent molecule that
possesses higher protein stability with relative ease of manu-
facturing processes for pharmaceutical applications. Blocking
B7 binding sites with CTLA4Ig has been reported to compete
with CD28 binding to B7 molecules and thus to prevent an-
tigen-specific activation of T cells, thus rendering T cells un-
responsive or anergic (4). Specifically, CTLA4Ig has been
used to prevent organ transplant rejection (5,6), lupus-like
autoimmune disease (7), experimental autoimmune enceph-
alomyelitis (8,9), autoimmune oophoritis in experimental
models (10), and asthmatic lung inflammation (11). The effi-
cacy of CTLA4Ig has also been tested in phase I clinical trials
for patients with psoriasis (12).
Despite the success in using the soluble CTLA4Ig fusion
protein in clinical settings, its full potential has yet to be
achieved. Current treatment regimens with CTLA4Ig solu-
tion involve multiple injections of high doses at a high fre-
quency, which may be burdensome to patients and may lead
to undesirable side effects. The problems associated with the
current formulation of soluble CTLA4Ig can be largely solved
by a delivery strategy to enhance the pharmacokinetic and
pharmacodynamic parameters (13–15). We hypothesized in
this report that the efficacy of CTLA4Ig could be altered and
greatly improved by conjugation to sterically stabilized, long-
circulating liposomes.
Liposomes have been used widely as carriers for a range
of both hydrophilic and hydrophobic diagnostic or therapeu-
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tic agents (16). Formulation in liposomes provides a larger
drug payload per particle, protects encapsulated agents from
metabolic processes, and increases affinity through multiva-
lent binding to target cells. The lipid composition of lipo-
somes can be modified for specific needs thus acquiring ad-
ditional desirable properties, such as prolonged circulatory
half-life in plasma, ability to complex with nucleic acids to
mediate gene delivery or genetic regulation, and capacity to
deliver encapsulated contents to the cytosol of cells through
the endosomal/lysosomal pathway (17,18). Conventional lipo-
somes have been shown to be rapidly cleared from plasma
circulation by the reticuloendothelial system (RES). Steri-
cally stabilized liposomes containing 5–10 mol % PEG-PE,
polyethylene glycol (PEG) of 50–250 chain length conjugated
to phospatidylethanolamine (PE), however, exhibit retarded
uptake by the RES and thus have a prolonged circulatory
half-life (16,19). Additionally, a functional maleimide can be
attached to the terminal end of the PEG for conjugating pro-
teins or other molecules to the liposome for targeted drug
delivery (20,21). Conjugation of ligands, functional proteins,
or monoclonal antibodies has been extensively explored, pri-
marily for targeting specific cells or tissues. The concept of the
so-called “immunoliposomes” is one example of such ap-
proaches (22,23). One of the most advanced immunoliposome
formulations is the anti-HER2 mAb conjugated to PEG-
liposomes carrying antitumor compound; PEGylated lipo-
somes were reported to accumulate in solid tumors, but
mostly extracellular in the interstitial space with no intracel-
lular distribution unless anti-HER2 antibodies were conju-
gated (24). The antitumor effect, mediated by ligation of
HER2 receptors by the mAb, was reported to be augmented
by liposomal conjugation. Our approach using CTLA4Ig is
analogous to that used for the anti-HER2 mAb-PEGylated
liposome strategy. One major difference of our system, and
perhaps an advantage in comparison with other systems, is
the fact that the intended target cells for CTLA4Ig-liposomes
are primarily antigen presenting cells like macrophages in
which liposomes have a natural propensity to accumulate
even without targeting.
In this study, we generated CTLA4Ig-liposomes and
tested its efficacy in blocking and downregulating B7 mol-
ecules as compared to free CTLA4Ig. We investigated its
efficiency using B7-transfected P815 cells and activated bone
marrow-derived macrophages (BMMs). Additionally, the fate
of B7-bound CTLA4Ig-liposomes was determined to support
the hypothesis that B7 molecules multivalently ligated by li-
posomal CTLA4Ig are induced to be internalized rapidly
along with the liposomes; B7 molecules have a long cell sur-
face half-life once expressed, and B7 ligated by soluble
CTLA4Ig are believed to stay most likely on the cell surface
while B7 bivalently ligated by anti-B7 antibody have been
reported to be internalized at 37°C (25).
Subsequently, limited in vivo experiments were con-
ducted to assess the targeting capability, biodistribution and
circulation time of CTLA4Ig-liposomes in a mouse model as
well as pancreatic islet transplant model. These studies dem-
onstrated the potential therapeutic advantages of liposomal
CTLA4Ig but an unexpected negative effect associated with
liposomal conjugation. Twenty-four hours after injection,
high levels of CTLA4Ig-liposome were accumulated in the
liver and spleen, which could be alleviated by simultaneous
injection of anti-FcR mAb. Regardless of circulation time,
however, twice as much CTLA4Ig-liposome was accumulated
in the kidney engrafted with pancreatic islets of Langerhans
compared to the contralateral control kidney. A careful
mechanistic investigation suggested that the circulation time,
and subsequently targetability and efficacy, of CTLA4Ig-
liposomes could be improved by modifying the extent of in-
teraction of Fc moiety of the CTLA4Ig with Fc receptors.
The results in this report suggest that this approach might
be useful for controlling the pharmacokinetic and biodistri-
bution profiles of CTLA4Ig, applicable to treatments of or-
gan transplantation scenarios and delivery of drugs site-
selectively within the immune system. Thus, liposomal formu-
lation of CTLA4Ig may become a potential strategy to
improve the function of CTLA4Ig by combining with the in-
trinsic characteristics of liposomes.
MATERIALS AND METHODS
Cell Culture
A hybridoma cell line, HB-197 secreting 2.4G2 mAb
(American Type Culture Collection, Manassas, VA, USA),
B7-1 transfected P815 cells and nontransfected P815 parental
cells (American Type Culture Collection, Rockville, MD,
USA) were grown in Dulbecco’s modified Eagles Medium
(DMEM, Gibco/BRL, Grand Island, NY, USA) containing
10% fetal bovine serum (FBS) supplemented with non-
essential amino acids, -mercaptoethanol (-ME), HEPES
and penicillin/streptomycin (Gibco/BRL).
Mouse bone marrow-derived macrophages were ob-
tained from the femurs of female BALB/c mice (The Jackson
Laboratory, Bar Harbor, ME, USA) and cultured in vitro as
described (26). In brief, the mice were euthanized according
to institutional guidelines and dissected to expose the whole
femur. The femur was removed and the marrow was irrigated
twice with 5 mL of DMEM containing 10% FBS. The har-
vested cells were washed with 10% FBS-DMEM by centrifu-
gation for 5 min at 200 × g. The cells were resuspended in
BMM media (DMEM containing 10% FBS, 30% L cell con-
ditioned media (the source of Macrophage Colony Stimulat-
ing Factor), and -ME), counted, and 4 × 106 cells were plated
onto 100-mm flasks.
Animals
C3H, BALB/c and C57BL/6 mice were purchased from
the Jackson Laboratory and were kept at the Pathogen-Free
animal facilities of the University of Michigan and the Uni-
versity of Chicago. In vivo experimental protocols were used
according to approved institutional guidelines.
Liposome Preparation
Liposomes composed of egg phosphatidylcholine (PC,
Avanti Lipid Inc., Alabaster, AL, USA) and cholesterol
(Calbiochem, La Jolla, CA, USA) in a 2:1 molar ratio were
prepared as described before (19,20,24). Where indicated, 2
mole % of maleimideparabenzoic-PE (MPB-PE), a PE de-
rivative with a functional maleimide, was incorporated into
the lipid mixture to allow conjugation of CTLA4Ig to the
surface of the liposome. After mixing, solvent was evaporated
(Rotovapor R-200, Buchi), and the multilamellar lipid film
was hydrated with either HBSE (10 mM HEPES, 140 mM
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NaCl, 1 mM EDTA, pH 7.0) or 5-hydroxypyranine trisulfo-
nate (HPTS; 35 mM in HBSE, pH 7.0, Molecular Probes,
Eugene, OR, USA). The lipid solution was then subjected to
four freeze-thaw cycles and four cycles of membrane extru-
sion (Lipex, Vancouver, BC, Canada) through 0.1-m pore
polycarbonate filters (Nucleopore Corning, Acton, MA,
USA). After extrusion, the liposomes were kept at 4°C under
argon until the time of the experiment. For animal studies,
liposomes were prepared by lipid film hydration as above
except the lipid composition was 10 mole % PEG-PE, PC,
cholesterol, 1,2 Diacyl-SN-Glycero-3-Phosphoethanolamine-
N-{Methoxy-(polyethyleneglycol)-2000} (PEG-PE, Avanti
Polar Lipids), and maleimide-PEG-PE (MAL-PEG-PE) in a
9:5:0.75:0.25 molar ratio. The control liposomes without con-
jugated protein were composed of PC, cholesterol, and PEG-
PE in a 9:5:1 molar ratio. Both CTLA4Ig-conjugated and
non-conjugated liposomes contained 50 Ci of 3H-labeled
cholesteryloleate ether (Amersham Biosciences, Piscataway,
NJ, USA) per mole of phospholipid. The lipid films were
hydrated with HBSE, freeze/thawed as above and extruded
sequentially through 0.2-m, 0.1-m and 0.05-m polycar-
bonate filters (four times each) to make liposomes of approxi-
mately 100-nm average diameter.
CTLA4Ig Conjugation to Liposomes
Modification of CTLA4Ig with
Succinimidyl-S-Acetylthioacetate (SATA)
The human CTLA4Ig (obtained as a gift from Repligen
Corporation, Cambridge MA, USA; Ref. 15) was modified
with SATA following the protocol described previously (27).
Briefly, CTLA4Ig in phosphate-buffered saline (PBS;
137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM
KH2PO4, 9 mM CaCl2·2H2O, 5 mM MgCl2·6H2O, pH 7.4) at
a concentration of 2 mg/mL was incubated with SATA solu-
bilized in dimethyl formamide for 25 min at 25°C with gentle
mixing. The molar and volume ratios of CTLA4Ig to SATA
were 1:20 and 1:100, respectively. Unreacted SATA was re-
moved by dialysis at 4°C overnight. Deacetylation was per-
formed by incubating with deacetylation solution (0.5 M hy-
droxylamine, 50 mM sodium phosphate, 25 mM EDTA, pH
7.0) for 2h at 25°C right before mixing with liposomes.
Coupling to Maleimide-PE-Containing Liposome and
Separation of Free CTLA4Ig from Liposomes
Maleimide-containing liposomes were added to the
deacetylated CTLA4Ig-linked SATA (CTLA4Ig-SATA) so-
lution with the lipid to CTAL4Ig molar ratio of 290:1, and
incubated overnight with gentle mixing at 4°C under Argon
gas. Following conjugation, free unconjugated CTLA4Ig was
removed by gel filtration (1 × 20 cm Sepharose CL-4B col-
umn, Amersham Biosciences, Piscataway, NJ, USA), eluant
was collected. The amount of conjugated CTLA4Ig and phos-
pholipid in the liposomal fraction from the column was as-
sayed by quantitative sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and phosphate assay (17,27), respectively.
The number of conjugated CTLA4Ig molecules per liposome
was calculated based on liposome size of 100 nm.
Purification of anti-FcR mAb 2.4G2
A hybridoma cell line HB-197 was cultured in DMEM
with 4 mM glutamine, 10% FBS, and penicillin/streptomycin
in a roller bottle, and the antibody from the culture superna-
tant was affinity purified using a Protein G Sepharose column
(Amersham Biosciences, Piscataway, NJ, USA)
Assay for Available B7 Molecules: Targeting of
CTLA4Ig-Liposomes to B7 Molecules on the Cell Surface
Cultured P815 cells and B7-1 transfected P815 cells were
harvested and washed twice with PBS with 0.5% bovine se-
rum albumin. Nonspecific Fc receptor binding was blocked by
the addition of 2.4G2 mAb to 0.5 × 106 cells and incubated for
10 min at room temperature. Ten microliters of CTLA4Ig-
liposomes or controls at different dilutions were added to the
cells in suspension and incubated for 30 min at 4°C. Ten
microliters of murine CTLA4Ig-FITC (500 g/mL) were
added to the cells and further incubated for 45 min at 4°C.
Cells were then washed twice with 0.5% bovine serum albu-
min PBS and were analyzed by flow cytometry.
Internalization Study Using CTLA4Ig-Liposomes
Containing Encapsulated HPTS
Murine bone marrow-derived macrophages were plated
on cover slips in 24-well culture plates on culture day 7 at a
density of 20,000 cells per coverslip. After 24 h, the cells were
activated with 25 g/mL of lipopolysaccharide from Esch-
erichia coli (Sigma, St. Louis, MO, USA) and 250 U/mL of
interferon- (Genzyme, Cambridge, MA, USA) for 24 h.
Cells were first incubated with CTLA4Ig-liposomes encapsu-
lating HPTS for 45 min at 4°C (28,29). Where indicated, an
excess amount of free CTLA4Ig (125 g/ml) was added to
compete binding to B7s. After washing three times, cells were
further incubated for 1 h either at 4°C or at 37°C to allow
internalization. The cells were observed under a fluorescence
microscope (Zeiss, Axiovert 135TV) equipped with alternat-
ing excitation filters (405 nm and 450 nm with 10 nm band-
pass) and the images were monitored and analyzed by Meta-
morph Image Analysis System (Universal Imaging, West
Chester, PA, USA).
Allogenic Mixed Lymphocyte Reaction (MLR).
Lymph node cells from BALB/c mice were harvested
and used as responder T cells for allogenic MLR. The stimu-
lator cells were prepared from the spleen of C57BL/6 mice
irradiated (2000 rad) and depleted of T cells. Primary MLR
cultures were performed in 96-well plates consisting of 2 × 105
responder BALB/c T cells and 2 × 105 B6 splenic cells in a
total volume of 0.2 mL. Where indicated, free CTLA 4 Ig,
liposomal CTLA 4 Ig, or empty liposomes were added to the
well. Mixed cells were incubated for 96 h at 37°C and pulsed
with 3H-thymidine for the last 16 h. The amount of 3H-
thymidine uptake by proliferating T cells in each well was
monitored by harvesting cells at the end of 16 h pulse and
scintillation counting.
Mouse Islet Isolation and Transplantation
Mouse Islet Isolation
Murine islets were isolated from BALB/c as described
previously (30). Briefly, animals were killed by cervical dis-
location, and the pancreas was exposed and injected with
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Hanks’ balanced salt solution (Mediatech, Herndon, VA,
USA) containing 0.5 mg/mL collagenase P (Roche Diagnos-
tics Corporation, Indianapolis, IN, USA) via the common bile
duct until distension was achieved. Digestion was performed
at 37°C for 17 min with gentle shaking and terminated by the
addition of cold RPMI containing 10% FBS and 2 mM L-
glutamine (GIBCO, Carlsbad, CA, USA). Islets were purified
on Euro-Ficoll (Sigma, St. Louis, MO) gradients by centrifu-
gation at 900 × g for 15 min, routinely yielding preparations of
>90% purity. Islets were hand-picked, counted, and scored
for size. Subsequently, islets were rested and stabilized by
culturing in RPMI 1640 medium supplemented with 11 mM
glucose, 2 mM L-glutamine, 10% FBS, 100 U/mL penicillin,
and 100 g/mL streptomycin (complete medium) for 2 h be-
fore transplantation.
Islet Transplantation under the Kidney Capsule
The isolated islets from BALB/c mice were transplanted
under the capsule of the left kidney of recipient C57BL/6
mice. 500 handpicked isolated islets were pelleted by brief
centrifugation at 200 × g. With the mouse under isoflurane
anesthesia, the left kidney was exposed through a lumbar
incision. A capsulotomy was performed in the lower pole of
the kidney using a 30-gauge needle, and the tip of the tubing
was advanced under the capsule of the upper pole, the site of
final injection. The capsulotomy was cauterized after delivery
of the islets, and the animal was closed using 5-O silk suture.
Animals were allowed to recover under a heat lamp and
blood glucose levels were checked.
Biodistribution of CTLA4Ig-Liposomes in Mice
One day after transplant surgery, mice were injected with
radio-labeled CTLA4Ig-conjugated PEGylated liposomes via
the tail vein. Where indicated, mice were injected intraperi-
tonealy with 100 g 2.4G2 mAb 90 min before liposome in-
jection, and 50 g 2.4G2 was also co-injected with the lipo-
some formulation. Blood samples of approximately 100 L in
volume were taken at 1 h, 4 h, and 24 h postinjection by
retroorbital puncture. At 24 h, animals were weighed, eutha-
nized according to the institutional protocol, and the major
organs were removed and weighed. Portions of each organ
(approximately 0.1 g) were solubilized with Solvable (Pack-
ard Instruments, Meridan, CT, USA) for 2–24 h at 60°C.
Subsequently, the samples were decolorized using 30% H2O2
(Fisher, Fair Lawn, NJ), and the radioactivity was counted
using Hionic Fluor Scintillation Cocktail (Packard Instru-
ments, Meridan, CT, USA) on a Beckman LS6000SC Beta
counter. The total blood volume was estimated to be 7.7% of
total body weight (31). The total radioactivity of the blood
and other organs was extrapolated from the portions that
were counted, and radioactivity due to the blood content of
each tissue was accounted for according to a previously re-
ported method (32). The radioactivity measured in each or-
gan was divided by the total dose injected into each animal to
calculate the percent injected dose in each organ.
RESULTS
CTLA4Ig-Liposomes Bind to B7-Expressing Cells with
Higher Affinity
To assess targeting of CTLA4Ig-conjugated liposomes
and their ability to block the binding sites of B7 molecules
expressed on the cell surface, we prepared, tested and com-
pared CTLA4Ig-liposomes with soluble CTLA4Ig by per-
forming competitive binding assays using two cell culture sys-
tems: 1) parental and B7-1 transfected P815 cells; and 2) ac-
tivated and nonactivated BMMs. The average number of
CTLA4Ig molecules conjugated per liposome used in this
study was approximately between 100 and 300, which was
according to the calculation based on the experimentally de-
termined conjugation efficiency of CTLA4Ig and the average
liposome size of 100 nm in diameter (data not shown).
Cells were pre-incubated with either soluble free
CTLA4Ig or CTLA4Ig-liposomes at varying concentrations,
and subsequently incubated with FITC-labeled CTLA4Ig at
4°C to monitor the remaining unblocked B7 or the fraction of
the prebound B7 that would be competed off by a high con-
centration of CTLA4Ig-FITC. The binding of CTLA4Ig-
FITC was monitored by flow cytometry. As shown in Fig. 1A,
CTLA4Ig-FITC bound to P815 cells expressing B7-1 and
showed a single peak (curve p, Fig. 1A, upper panel).
CTLA4Ig-FITC did not bind to P815 parental cells not ex-
pressing B7-1 (curve n, Fig. 1A), confirming that CTLA4Ig-
FITC binds to B7-1 in a specific manner. Pre-incubation of
cells with 50 g/mL of liposomal CTLA4Ig completely
blocked the binding of additional CTLA4Ig-FITC to B7 mol-
ecules (curve p shifts to curve a, Fig. 1A, upper panel);
whereas preincubation with free CTLA4Ig (62.5 g/mL)
blocked B7 binding sites only partially (curve b, Fig. 1A, up-
per panel), which showed that liposomal CTLA4Ig has a
higher affinity or avidity to B7-1 than free CTLA4Ig. The
increased binding of liposomal CTLA4Ig to B7-1 was specific
only to liposome-conjugated CTLA4Ig as only 50% of B7-1 in
transfected P815 cells could be blocked by pre-incubating the
cells with 62.5 g/ml free or 62.5 g/ml free CTLA4Ig mixed
with blank liposomes (curve c, Fig. 1A, lower panel). Control,
blank liposomes without conjugated CTLA4Ig showed no
blocking (curve d, Fig. 1A, lower panel).
A similar result was obtained using primary cultures of
bone marrow-derived macrophages (Fig. 1B), which often are
classified as professional APCs. Upon activation with LPS
and IFN, the level of B7 molecules on the BMM surface
increased as detected by CTLA4Ig-FITC binding (from curve
a to b, Fig. 1B). Preincubation of cells with 50 g/ml of lipo-
some-conjugated CTLA4Ig for 1h at 4°C blocked nearly
100% of the B7 molecules on activated BMMs (curve c, Fig.
1B).
To further investigate dose dependency, specificity, and
binding avidity of liposomal CTLA4Ig, B7-1-transfected P815
cells were preincubated with varying concentrations of either
free CTLA4Ig, liposomal CTLA4Ig, CTLA4Ig mixed with
non-CTLA4Ig-liposomes (i.e., blank liposomes), liposomes
conjugated with a non-specific antibody 10A6, or blank lipo-
somes alone, and subsequently followed by staining with
CTLA4Ig-FITC (Fig. 2). Free CTLA4Ig blocked 50% of cell
surface B7 molecules at approximately 100 g/ml, as moni-
tored by CTLA4Ig-FITC staining (filled circle, Fig. 2). The
liposome-conjugated CTLA4Ig had significantly enhanced
blocking efficiency, showing 50% blockage at approximately
10 g/ml CTLA4Ig (filled triangle, Fig. 2). This enhanced
avidity could not be achieved by simply mixing free CTLA4Ig
with empty liposomes as the CTLA4Ig mixed with blank li-
posomes behaved the same as free CTLA4Ig (open circle,
Fig. 2), demonstrating that conjugation of CTLA4Ig onto li-
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posomes was required. The B7 specificity of the CTLA4Ig-
liposome-mediated blocking was shown by the lack of B7
blocking using the liposomes conjugated to irrelevant anti-
bodies, 10A6 mAb (open triangle, Fig. 2). These data quan-
titatively support the hypothesis that liposomal CTLA4Ig is
superior to free CTLA4Ig in blocking the B7 molecules, pre-
sumably through a multivalent ligand effect, and that
CTLA4Ig-conjugated liposomes can be used to efficiently tar-
get liposomes to B7 expressing cells and block B7 molecules.
Liposomal CTLA4Ig Undergo Rapid Internalization upon
B7 Ligand Binding
To further monitor binding morphologically and deter-
mine the cellular fate of CTLA4Ig-conjugated liposomes, a
Fig. 2. A comparison of blocking of B7 expressed on P815 cells by
free CTLA4Ig and liposomal CTLA4Ig. P815 cells were preincubated
with free CTLA4Ig (filled circle), liposomal CTLA4Ig (filled tri-
angle), mixture of empty liposomes and free CTLA4Ig (open circle),
or control mAb 10A6 conjugated to liposomes (open triangle). Sub-
sequently unblocked B7 was detected with CTLA4Ig-FITC staining
and flow cytometry.
<
Fig. 1 (continued). Curve a shows blocking of CTLA4Ig-FITC bind-
ing to B7-transfected P815 cells by liposomal CTLA4Ig (50 g/mL);
curve b shows blocking of CTLA4Ig-FITC binding to B7-transfected
P815 cells by free CTLA4Ig (62.5 g/mL); curve c shows blocking of
CTLA4Ig-FITC binding to B7-transfected P815 cells by free
CTLA4Ig (62.5 g/mL) and empty liposomes administered simulta-
neously; and curve d shows blocking of free CTLA4Ig binding to
B7-transfected P815 cells by empty liposomes. B, Flow cytometric
data showing CTLA4Ig-FITC binding to B7 expressed by activated
macrophages and blocking of this interaction by liposomal CTLA4Ig.
Curve a shows the basal level of CTLA4Ig-FITC binding to resting
macrophages without activation; curve b shows the level of
CTLA4Ig-FITC binding to activated macrophages, and curve c shows
blocking of CTLA4Ig-FITC binding to activated macrophages by li-
posomal CTLA4Ig.
Fig. 1. A, Flow cytometric data showing CTLA4Ig labeled with FITC
(CTLA4Ig-FITC) binding to P815 cells expressing of B7 and blocking
of this interaction by liposomal CTLA4Ig formulations. The negative
control (curve n) shows the basal level of CTLA4Ig-FITC binding to
P815 cells, and the positive control (curve p) shows the level of
CTLA4Ig-FITC binding to P815 cells transfected with a B7-1 gene.
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pH-dependent fluorescent dye, HPTS, was encapsulated in-
side the liposomes, and their intracellular trafficking was in-
vestigated using epifluorescence microscopy. At physiologic
pH, HPTS has fluorescence excitation peaks at both 405 nm
and 450 nm. The fluorescent intensity with 450 nm excitation,
however, decreases as pH drops while that with 405 nm ex-
citation increases (29,33). The CTLA4Ig-liposomes were in-
cubated with BMMs for 1 h at 4°C for binding, and cells were
washed and monitored on a live cell stage. CTLA4Ig-
liposomes showed minimal binding to nonactivated BMMs
(Fig. 3a), which was consistent with the low expression level
of B7 on BMM observed by flow cytometry (Fig. 1B). When
cells were activated, as the expression of B7 was induced by
activation, binding of CTLA4Ig-liposomes to BMMs was
clearly augmented (Fig. 3b). The similar intensity of the cell-
associated HPTS fluorescence at 405 nm and at 450 nm exci-
tation wavelength indicates the CTLA4Ig-liposomes re-
mained on the cell surface at 4°C and were not internalized.
CTLA4Ig-liposome binding to BMMs was abrogated by pre-
incubating cells with excess free CTLA4Ig, which supported
the idea that the CTLA4Ig-liposome binding seen in this mi-
croscopy study was predominantly mediated by the
CTLA4Ig/B7 interaction (Fig. 3c). When cells were warmed
to 37°C and incubated for 1 h, the fluorescence signal previ-
ously seen on the cell surface migrated to the perinuclear
region of the cells. Additionally, the HPTS signal at 450 nm
excitation weakened while the signal at 405 nm became dis-
tinct (Fig. 3d), indicating that CTLA4Ig-liposomes were in-
ternalized into low pH compartments upon specific binding to
B7 molecules on BMMs.
Blockade of Allogenic MLR with CTLA4Ig-Liposomes
The effectiveness of CTLA4Ig-liposomes in blocking the
surface expressed B7 molecules on APCs, thereby attenuat-
ing T cell activation, was investigated. In order to do this, the
proliferation and consequent incorporation of 3H-thymidine
in the T cells of BALB/c mouse lymph nodes were monitored
when the T cells were mixed with the APCs of C57BL/6
spleen. The 3H-thymidine uptake was effectively inhibited by
CTLA4Ig-liposomes incubated during the 96 h mixed lym-
phocyte culture (Fig. 4). The inhibition was concentration-
dependent, with 50% attenuation at 100 ng/ml CTLA4Ig
concentration, while blank liposomes without CTLA4Ig con-
jugation did not have any effect on the MLR. The effective-
Fig. 3. Epifluorescence microscopic images of macrophages treated
with CTLA4Ig-conjugated liposomes containing 5-hydroxypyranine
trisulfonate. Cells were incubated with HPTS-containing CTLA4Ig-
liposomes at 4°C for 1 h, washed, and followed by various additional
treatments noted in the caption including activation, free excess
CTLA4Ig, and warming up the cells to 37°C. The cell-associated
HPTS-containing CTLA4Ig-liposomes were visualized in an epifluo-
rescence microscope. Fluorescence images of macrophages with ex-
citation at 405 nm and at 450 nm are shown next to each other.
Fig. 4. Inhibition of mixed lymphocyte reaction by CTLA4Ig-
liposomes. Liposomes with and without conjugated CTLA4Ig were
added to mixed lymphocyte culture (2 × 105 responder BALB/c T
cells and 2 × 105 B6 splenic cells in a total volume of 0.2 mL in a
96-well microplate well) at various concentrations during 96 h culture
period. The cells were pulsed with 3H-thymidine for the last 16 h, and
the amount of 3H-thymidine uptake by proliferating T cells in each
well was monitored by harvesting cells and scintillation counting.
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ness of CTLA4Ig, however, was not significantly improved
over free CTLA4Ig as monitored by this assay.
Blood Circulation and Biodistribution
of CTLA4Ig-Liposomes
To determine plasma circulation time and biodistribu-
tion, CTLA4Ig-conjugated and control PEG-PE-containing
liposomes (i.e., stealth) liposomes were labeled with 3H-
cholesteryl oleate ether and injected into C57BL/6J mice with
allogeneic pancreatic islet transplants in one kidney. Islets
were transplanted under the capsule of the left side kidney
while the right side kidney was left untouched as control side.
At 1 h, 4 h and 24 h postinjection, 100–200 l of blood was
sampled, and at the 24 h postinjection, the radioactivity re-
maining in the blood and that accumulated in major organs
were measured.
Investigation of the plasma levels and biodistribution of
liposomes with and without CTLA4Ig conjugation showed
that the CTLA4Ig conjugation resulted in increased accumu-
lation in RES and correspondingly decreased circulation time
in relative comparison with the control stealth liposomes
(Table I); the half-life of the CTLA4Ig-conjugated liposomes
in the blood circulation was approximately 0.5 h in compari-
son with that of the non-CTLA4Ig-liposomes, which was ap-
proximately several hours (Fig. 5). In mice injected with li-
posomes without conjugated CTLA4Ig (control liposomes),
18.6% of injected dose of liposomes was circulating in the
blood (Table I). In contrast, only 2.2% of CTLA4Ig-
liposomes were circulating in the blood. Reduced blood cir-
culation of CTLA4Ig-liposomes correlated with increased ac-
cumulation in RES including the liver (65.5% vs. 21.7%).
Based on these data, we hypothesized that the recognition of
the Fc portion of CTLA4Ig by Fc receptor expressed on mac-
rophages in RES, rather than liposomal CTLA4Ig binding to
B7 on APCs, was the major mechanism for the increased
uptake by RES of the liposomes with CTLA4Ig conjugation
and the consequent short circulation time. This hypothesis
was tested by comparing the blood circulation of CTLA4Ig-
liposomes in wild-type mice and in B7-1/B7-2 knockout (KO)
mice. The results shown in Table I strongly indicate that
CTLA4Ig binding to B7 is not the major interaction for the
enhanced uptake by the RES. Regardless of B7 presence in
mice, the blood circulation profiles of these liposomes were
not affected (Fig. 5). The biodistribution of CTLA4Ig-stealth
liposomes at 24 h postinjection was also very similar in wild-
type and B7 KO mice (Table I). High levels of CTLA4Ig-
conjugated liposomes were localized to the liver and spleen at
24 h postinjection, whereas, much more of the control lipo-
somes remained in circulation and less accumulated in RES.
To further confirm that the decreased circulation time of
CTLA4Ig liposomes was due to Fc receptor-mediated uptake,
mice were pre-injected with the FcR-blocking 2.4G2 mAb
before the administration of CTLA4Ig-stealth liposomes. In
both wild-type and B7 KO mice, animals preinjected with
2.4G2 showed increased CTLA4Ig-liposome levels in circula-
tion at 1 and 4 h after injection (Table II), supporting the
hypothesis that decreased circulation of the CTLA4Ig-stealth
liposomes was predominantly due to Fc receptor-mediated
uptake.
Circulation of liposomes in mice with allogeneic islet cell
transplants was not different from that in mice without trans-
plants. The percentage of CTLA4Ig-liposomes localized to
the transplanted kidney was also reduced as compared to
control liposomes, presumably due to the lower level of blood
circulation. As the circulation time of control liposomes was
Table I. Tissue Distribution of Liposomes at 24 h Post-Injection
B7 knockout Wild type
− CTLA4Ig + CTLA4Ig − CTLA4Ig + CTLA4Ig
Blood 23.4% (±3.7%) 3.7% (±1.9%) 18.6% (±3.1%) 2.2% (±0.5%)
Liver 21.5% (±1.1%) 64.9% (±2.8%) 21.7% (±2.7%) 65.5% (±10.6%)
Spleen 0.6% (±0%) 0.2% (±0.1%) 0.5% (±0.1%) 0.1% (±0%)
Lung 2.0% (±0.3%) 4.2% (±1%) 2.2% (±0.1%) 6.2% (±0.5%)
Kidney (transplant) 2.4% (±0.4%) 0.7% (±0.1%) 2.0% (±0.3%) 0.7% (±0.1%)
Kidney (control) 0.9% (±0.2%) 0.3% (±0%) 0.9% (±0.1%) 0.3% (±0.1%)
Note: Values are expressed as mean (± SD)
Fig. 5. Percent injected dose of liposomes in blood circulation at 1, 4,
and 24 h postintravenous injection. Liposomes with (filled square and
circle) and without (open square and circle) CTLA4Ig conjugation
were labeled with 3H cholesteryloleate ether and injected into either
normal mice (squares) or B7 knockout mice (circles). The amounts of
radioactivity in blood samples collected at various timepoints post-
injection are plotted as percent of injected dose. Data are plotted as
mean ± SD, n  4.
Targeting B7 Costimulatory Molecules by CTLA4Ig-Liposomes 1245
significantly longer, approximately three times more control
stealth liposomes accumulated in the kidney than CTLA4Ig-
stealth liposomes (2.0% vs. 0.7%, Table I). Regardless of
whether CTLA4Ig was conjugated or not, however, the lipo-
somes accumulated approximately 2-fold more in the trans-
plant side kidney than in the non-transplant control side, and
this trend was observed both in wild type and B7 KO mice
(Table I).
DISCUSSION
In this study, we explored the feasibility of generating
immunoliposomes using CTLA4Ig and further examined
their effectiveness in vitro and in vivo. Our results show that
conjugating CTLA4Ig onto the surface of liposomes improves
the avidity of CTLA4Ig binding to B7 molecules and induces
their internalization upon binding. When the CTLA4Ig mol-
ecules are conjugated to phospholipids in the bilayers of li-
posomes, at approximately 100–300 CTLA4Ig per liposome,
the multivalent effect leading to increased avidity is antici-
pated. As the lipid-conjugated CTLA4Ig molecules possess
lateral mobility within the lipid membrane of liposomes, they
are able to ligate multiple B7 molecules on cell surface be-
yond the initial binding of the first CTLA4Ig molecule to a B7
molecule. Consistent with this, the data from the cell culture
study demonstrated that CTLA4Ig-liposomes could block
100% of B7 molecules on either B7 transfectant cells or ac-
tivated bone marrow-derived macrophages at a concentration
10-fold lower than the level needed using free soluble
CTLA4Ig, in which 5-fold excess amount of CTLA4Ig-FITC
could not compete off the prebound liposomal CTLA4Ig.
This was only observed upon covalent conjugation of
CTLA4Ig onto liposomes as the simple mixture of CTLA4Ig
and liposomes behaved identically to free CTLA4Ig. The
blocking was specific as the irrelevant antibody 10A6 conju-
gated to liposomes did not block the subsequent binding of
FITC-CTLA4Ig.
One of the distinct features of the liposome-conjugated
ligand would be its characteristic to induce internalization,
upon cell surface binding, of the liposomal ligand-receptor
complex. This propensity is increasingly powerful not only for
achieving long-term depletion of receptors upon internaliza-
tion into endolysosomal compartments, but also for obtaining
intracellular delivery of drugs that can be encapsulated inside
liposomes. The receptor level on the cell surface can be down-
regulated, beyond a simple blockage of the receptor binding
sites, if the liposomal ligands are co-internalized with the re-
ceptors and delivered to the lysosomal degradation pathway.
Thus for blocking B7 sites on macrophage surface, the lipo-
somal CTLA4Ig could have an added effect beyond simple
binding-mediated blockade of B7 by soluble CTLA4Ig. The
data using HPTS, a pH-sensitive fluorophore, inside the
CTLA4Ig-liposomes strongly support this possibility.
The biologic activity of CTLA4Ig-liposomes in attenuat-
ing the allogenic MLR-mediated T cell activation and prolif-
eration in the ex vivo cell culture assay was effective at lipo-
somal CTLA4Ig concentrations  1 g/mL. This functional
test of CTLA4Ig conjugated to liposomes is important to
demonstrate the effectiveness beyond binding assay in cell
culture and to move the formulation to animal models. The
enhanced inhibition of B7-mediated costimulation, however,
was not observed using this 96 h continuous incubation pro-
tocol of the standard allogenic MLR assay. This is mostly
likely due to a diminished effect of avidity differences be-
tween free and liposome-conjugated CTLA4Ig during the
long incubation period, which perhaps does not accurately
mimic the in vivo situation.
By conjugating CTLA4Ig molecules to the terminal end
of PEG in the PEG-PE-containing liposomes (i.e., stealth li-
posomes), we also tested if the prolonged circulation charac-
teristic of PEG-PE-containing liposomes is retained. One ap-
parent disadvantage of the liposomal CTLA4Ig in its current
formulation used in this study was its binding to RES, espe-
cially liver, thus lowering the level of blood circulation. The
data presented show that the CTLA4Ig conjugation signifi-
cantly reduced the circulation time of PEG-PE-containing
stealth liposomes and increased their uptake by liver and
spleen. This was observed both in wild type and in B7 KO
mice indicating the uptake by RES is most likely not medi-
ated by the specific interaction between CTLA4Ig and B7.
The half-life of the CTLA4Ig-conjugated liposomes in the
blood circulation of both B7 KO and wild type mice was
approximately 0.5 h, whereas the half-life of the non-
CTLA4Ig-liposomes was several hours both in wild type and
in B7 KO mice (Fig. 5). By 24 h after injection, almost no
CTLA4Ig-conjugated liposomes remained in circulation in B7
KO and wild type mice; however, approximately 25% of the
non-conjugated liposomes were in circulation in B7 KO and
wild type mice. The nature of enhanced RES uptake is prob-
ably the interaction of the Fc moiety of CTLA4Ig on the
liposome surface with FcR expressed on tissue macrophages
in RES as supported by the 2.4G2 anti-FcR mAb experiment
shown in Table II. Several modes of molecular interaction
between immunoliposomes with cells exist: 1) nonspecific li-
posome-cell interactions that might be reduced to minimal
upon incorporation of PEG-PE; 2) specific interaction of tar-
geting motifs, B7-binding site of CTLA4Ig in our case, with
corresponding cell surface receptors; and 3) general interac-
tion of the Fc portion of liposome-conjugated immunoglobu-
lins with cell surface Fc receptors predominantly expressed on
antigen presenting cells. The last interaction (3) is modulated
by the type of Fc portion of the immunoglobulin used, the
density of IgG conjugated per liposome, and the orientation
of IgG on the liposome surface. As it has been reported that
the number of IgG per liposome in the range used in our
report may induce enhanced recognition by Fc receptors (21),
a careful investigation into the rate of liposome clearance as
a function of CTLA4Ig density in our system will be neces-
sary. Moreover, the CTLA4Ig molecules on liposomes, using
the current conjugation protocol, are randomly oriented thus
resulting in non-preferential binding between CTLA4 and Fc
Table II. Percent Injected Liposome in Circulation at 1 and 4 h
Post-Injection









1 h 9.0% (±1.1%) 16.3% (±2.4%) 15.50% 20.9% (±1.3%)
4 h 0.6% (±0.2%) 1.3% (±0.3%) 4.72% 9.7% (±2.1%)




regions to their corresponding receptors on the macrophage
cell surface. This FcR-mediated uptake of immunoglobulin-
conjugated liposomes has been suggested previously in the
studies of immunoliposomes (34). One approach to reducing
the Fc-mediated uptake, in addition to controlling the density
of CTLA4Ig per liposome, would be to use other means of
conjugation to preferentially orient the CTLA4Ig molecules
on the liposomes. In addition, molecular engineering of
CTLA4Ig to reduce FcR binding will be necessary for increas-
ing blood circulation as well as specific targeting to the de-
sired sites.
Specific uptake of liposomes into the kidney having
transplanted islets, despite lower blood circulation, over that
into the contralateral control kidney, is notable and promis-
ing. CTLA4Ig-liposomes, even though they did not circulate
as long as non-CTLA4Ig liposomes, accumulated approxi-
mately 2-fold more in the islet-containing side than in the
contralateral, control kidney. This higher uptake into the ex-
perimental kidney was also observed without CTLA4Ig con-
jugation, which indicates passive targeting of liposomes in
general to inflammatory sites, rather than specific ligand-
receptor interaction-mediated active targeting, as suggested
by other models (19). The results in vivo using KO mice
further support that this increased kidney accumulation is not
mediated by CTLA4Ig/B7 interactions, but is due to passive
targeting as seen in other tumor targeting studies. The en-
hanced uptake into the experimental kidney with transplant
could be due to inflammation-mediated processes at the
transplantation site and enhanced extravasation of liposomes
into transplanted islets. Upon extravasation and passive ac-
cumulation within the transplant tissue, the B7/CTLA4Ig-
liposome interaction would be critical for the localized tar-
geting to B7-expressing APCs within the region. These prop-
erties make liposomes ideal for targeting to B7-expressing
APCs within engrafted sites. The typical volume of trans-
planted islets in the kidney was approximately 15 L. If 1% of
injected CTLA4Ig-liposomes accumulate in the transplanted
islets of the experimental side kidney, the local concentration
of CTLA4Ig that can be achieved with a 50 g dose would be
approximately 25 g/mL, which is at a sufficient level to in-
duce complete blockade of B7 binding sites. This suggests a
potential advantage of CTLA4Ig-liposomes, even in their cur-
rent formulation reported in this study, over free CTLA4Ig.
These results overall suggest the feasibility and the enormous
potential for significant increase in targeting to transplanted
islets. Taken together, our data provide a basis for a new
strategy to improve the efficacy of CTLA4Ig by formulating it
into the liposomes. Prolongation and optimization of circula-
tion of CTLA4Ig-PEG-liposomes using modified CTLA4Ig
will be a critical step to maximizing the benefit of CTLA4Ig-
liposomes. The data presented suggest that the optimization
of CTLA4Ig-stealth liposomes can be first achieved by modi-
fying the CTLA4Ig-liposomes for reduced FcR-mediated up-
take by the RES for the prolonged blood circulation time and
consequently enhancing the probability of specific targeting
via CTLA4/B7 interactions.
CONCLUSION
We have shown in this report the enhanced B7-blocking
capacity of CTLA4Ig when conjugated with liposomes using
cell culture studies. The CTLA4Ig-liposomes are shown to be
internalized into endocytic pathways upon binding to macro-
phages. The blood circulation time of CTLA4Ig-liposomes in
mice, however, was significantly shorter that that of the long-
circulation liposomes without CTLA4Ig conjugation due pri-
marily to the high uptake by the RES. The avid uptake by the
RES was not dependent on B7 expression in mice and was
most likely due to FcR-mediated recognition of liposomal
CTLA4Ig. The in vivo biodistribution results suggest a great
potential for augmenting the local concentration of
CTLA4Ig-liposomes in the transplant of islets, as well as an
obvious improvement strategy to reduce the uptake by the
RES, through the modification of the Fc region of the
CTLA4Ig, which can ultimately accomplish better pharmaco-
kinetics and further uptake into tissues containing trans-
plants.
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